|
1
|
Leiter U, Meier F, Schittek B and Garbe C:
The natural course of cutaneous melanoma. J Surg Oncol. 86:172–178.
2004.
|
|
2
|
Balch CM, Gershenwald JE, Soong SJ, et al:
Multivariate analysis of prognostic factors among 2,313 patients
with stage III melanoma: comparison of nodal micrometastases versus
macrometastases. J Clin Oncol. 28:2452–2459. 2010.
|
|
3
|
Balch CM, Gershenwald JE, Soong SJ, et al:
Final Version of 2009 AJCC Melanoma Staging and Classification. J
Clin Oncol. 27:6199–6206. 2009.
|
|
4
|
Hocker TL, Singh MK and Tsao H: Melanoma
genetics and therapeutic approaches in the 21st century: moving
from the benchside to the bedside. J Invest Dermatol.
128:2575–2595. 2008.
|
|
5
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002.
|
|
6
|
Curtin JA, Fridlyand J, Kageshita T, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005.
|
|
7
|
Garrido MC and Bastian BC: KIT as a
therapeutic target in melanoma. J Invest Dermatol. 130:20–27.
2010.
|
|
8
|
Kumar R, Angelini S, Snellman E and
Hemminki K: BRAF mutations are common somatic events in melanocytic
nevi. J Invest Dermatol. 122:342–348. 2004.
|
|
9
|
Gorden A, Osman I, Gai W, et al: Analysis
of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer
Res. 63:3955–3957. 2003.
|
|
10
|
Satyamoorthy K, Li G and Gerrero MR:
Constitutive mitogen-activated protein kinase activation in
melanoma is mediated by both BRAF mutations and autocrine growth
factor stimulation. Cancer Res. 63:756–759. 2003.
|
|
11
|
Gray-Schopfer VC, da Rocha Dias S and
Marais R: The role of B-RAF in melanoma. Cancer Metastasis Rev.
24:165–183. 2005.
|
|
12
|
Long GV, Menzies AM, Nagrial AM, et al:
Prognostic and clinicopathologic associations of oncogenic BRAF in
metastatic melanoma. J Clin Oncol. 29:1239–1246. 2011.
|
|
13
|
Rubinstein JC, Sznol M, Pavlick AC, et al:
Incidence of the V600K mutation among melanoma patients with BRAF
mutations, and potential therapeutic response to the specific BRAF
inhibitor PLX4032. J Transl Med. 8:672010.
|
|
14
|
Michaloglou C, Vredeveld LC, Soengas MS,
et al: BRAFE600-associated senescence-like cell cycle arrest of
human naevi. Nature. 436:720–724. 2005.
|
|
15
|
Pollock PM, Harper UL, Hansen KS, et al:
High frequency of BRAF mutations in nevi. Nat Genet. 33:19–20.
2003.
|
|
16
|
Edlundh-Rose E, Egyházi S, Omholt K,
Mansson-Brahme E, Platz A, Hansson J and Lundeberg J: NRAS and BRAF
mutations in melanoma tumours in relation to clinical
characteristics: a study based on mutation screening by
pyrosequencing. Melanoma Res. 16:471–478. 2005.
|
|
17
|
Goel VK, Lazar AJ, Warneke CL, Redston MS
and Haluska FG: Examination of mutations in BRAF, NRAS, and PTEN in
primary cutaneous melanoma. J Invest Dermatol. 126:154–160.
2006.
|
|
18
|
Poynter JN, Elder JT, Fullen DR, et al:
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma
Res. 16:267–273. 2006.
|
|
19
|
Omholt K, Platz A, Kanter L, Ringborg U
and Hansson J: NRAS and BRAF mutations arise early during melanoma
pathogenesis and are preserved throughout tumor progression. Clin
Cancer Res. 9:6483–6488. 2003.
|
|
20
|
Chapman PB, Hauschild A, Robert C, et al:
Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011.
|
|
21
|
Hauschild A, Grob JJ, Demidov LV, et al:
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre,
open-label, phase 3 randomised controlled trial. Lancet.
380:358–365. 2012.
|
|
22
|
Jakob JA, Bassett RL Jr, Ng CS, et al:
NRAS mutation status is an independent prognostic factor in
metastatic melanoma. Cancer. 118:4014–4023. 2012.
|
|
23
|
Karakousis CP: Therapeutic node
dissections in malignant melanoma. Semin Surg Oncol. 14:291–301.
1998.
|
|
24
|
Eggermont AMM, Suciu S, MacKie R, et al:
Post-surgery adjuvant therapy with intermediate doses of interferon
alfa 2b versus observation in patients with stage IIb/III melanoma
(EORTC 18952): randomized controlled trial. Lancet. 366:1189–1196.
2005.
|
|
25
|
Nowecki ZI, Rutkowski P and Michej W: The
survival benefit to patients with positive sentinel node melanoma
after completion lymph node dissection may be limited to the
subgroup with a primary lesion Breslow thickness greater than 1.0
and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol.
5:2223–2234. 2008.
|
|
26
|
Berd D, Mastrangelo MJ and Sato T:
Calculation of survival of patients with stage III melanoma. J Clin
Oncol. 23:94272005.
|
|
27
|
Gos A, Jurkowska M, Siedlecki JA, Michej
W, Wiater K, Switaj T, Kosela H and Rutkowski P: Comparison between
two widely used laboratory methods in BRAF V600 mutation
detection rate in FFPE clinical samples of stage III cutaneous
melanoma metastases to the lymph nodes. In: 17th
ECCO-38thESMO-32ndESTRO European Cancer Congress; 2013, Abstract
P465.
|
|
28
|
Lee JH, Choi JW and Kim YS: Frequencies of
BRAF and NRAS mutations are different in histological types and
sites of origin of cutaneous melanoma: a meta-analysis. Br J
Dermatol. 164:776–784. 2011.
|
|
29
|
Colombino M, Capone M, Lissia A, et al:
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases
in Patients With Melanoma. J Clin Oncol. 30:2522–2529. 2012.
|
|
30
|
Pont-Kingdon G, Gedge F,
Wooderchak-Donahue W, et al: Design and analytical validation of
clinical DNA sequencing assays. Arch Pathol Lab Med. 136:41–46.
2012.
|
|
31
|
Liu W, Kelly JW, Trivett M, et al:
Distinct clinical and pathological features are associated with the
BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest
Dermatol. 127:900–905. 2007.
|
|
32
|
Viros A, Fridlyand J, Bauer J,
Lasithiotakis K, Garbe C, Pinkel D and Bastian BC: Improving
melanoma classification by integrating genetic and morphologic
features. PLoS Med. 5:e1202008.
|
|
33
|
Ellerhorst JA, Greene VR, Ekmekcioglu S,
et al: Clinical Correlates of NRAS and BRAF Mutations in Primary
Human Melanoma. Clin Cancer Res. 17:229–235. 2011.
|
|
34
|
Akslen LA, Angelini S, Straume O, Bachmann
IM, Molven A, Hemminki K and Kumar R: BRAF and NRAS mutations are
frequent in nodular melanoma but are not associated with tumor cell
proliferation or patient survival. J Invest Dermatol. 125:312–317.
2005.
|
|
35
|
Houben R, Becker JC, Kappel A, et al:
Constitutive activation of the Ras-Raf signaling pathway in
metastatic melanoma is associated with poor prognosis. J Carcinog.
3:62004.
|
|
36
|
Moreau S, Saiag P, Aegerter P, et al:
Prognostic Value of BRAFV600 Mutations in Melanoma Patients After
Resection of Metastatic Lymph Nodes. Ann Surg Oncol. 19:4314–4321.
2012.
|
|
37
|
Rutkowski P, Nowecki ZI, Zdzienicki M, et
al: Cutaneous melanoma with nodal metastases in elderly people. Int
J Dermatol. 49:907–913. 2010.
|
|
38
|
Kretschmer L, Starz H, Thoms KM, et al:
Age as a key factor influencing metastasizing patterns and
disease-specific survival after sentinel lymph node biopsy for
cutaneous melanoma. Int J Cancer. 129:1435–1442. 2011.
|
|
39
|
Macdonald JB, Dueck AC, Gray RJ, Wasif N,
Swanson DL, Sekulic A and Pockaj BA: Malignant Melanoma in the
Elderly: Different Regional Disease and Poorer Prognosis. J Cancer.
2:538–543. 2011.
|
|
40
|
Menzies AM, Haydu LE, Visintin L, et al:
Distinguishing clinicopathologic features of patients with V600E
and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res.
18:3242–3249. 2012.
|
